Alex Garanto
banner
jandritu.bsky.social
Alex Garanto
@jandritu.bsky.social
Group leader developing molecular therapies for inherited neurometabolic and retinal diseases at the Radboudumc 👁️🧪🧬
From Barcelona,📍based in Nijmegen
🚨 PhD position available 🚨

👀 We are excited to announce a fully funded PhD position in our lab, focused on developing personalized induced pluripotent stem cell (iPSC)-based models to study inherited retinal diseases as part of the Lifelong VISION consortium!
July 21, 2025 at 8:45 AM
💡 Light matters 💡

Despite major advances in generating retinal cells in vitro, these cells are typically cultured in the dark. But why would cells develop light-sensitive features if there is no light around?
July 21, 2025 at 8:42 AM
Reposted by Alex Garanto
Congratulations Owen and many thanks to Alex and Amanda.
July 5, 2025 at 9:56 AM
Reposted by Alex Garanto
Congratulations Owen on your PhD defence 🥳🎉🥂huge thank you to examiners @jandritu.bsky.social and @amandajcarr.bsky.social
July 5, 2025 at 9:54 AM
🚨𝗙𝗶𝗻𝗮𝗹 𝗪𝗲𝗲𝗸 𝘁𝗼 𝗔𝗽𝗽𝗹𝘆 𝘁𝗼 𝟭𝟮 𝗙𝘂𝗹𝗹𝘆 𝗙𝘂𝗻𝗱𝗲𝗱 𝗣𝗵𝗗 𝗣𝗼𝘀𝗶𝘁𝗶𝗼𝗻𝘀 𝘄𝗶𝘁𝗵 𝗘𝗙𝗙𝗲𝗰𝗧🚨
🔬 Join an international network driving innovative treatments and delivery methods for a variety of disorders with leading experts in RNA therapeutics 🌍
🔗 𝗔𝗽𝗽𝗹𝘆 𝗻𝗼𝘄: euraxess.ec.europa.eu/jobs/296420
more info: www.effect-dn.eu
12 PhDs on Antisense oligonucleotide research to foster the full therapeutic potential of antisense technology across tissues
EFFecT (European Training Program to Foster the Full Therapeutic Potential of Antisense Technology across Tissues) is a Marie Skłodowska-Curie Doctoral Network (2025-2028), offering 12 PhD positions.
euraxess.ec.europa.eu
March 6, 2025 at 8:32 AM
5 Partners & 1 Associated partner of #EFFecT are present at SMOT (Synergistic Meeting on Oligonucleotide Therapeutics) celebrating #rarediseaseday.@radboudumc.bsky.social @dutchantisense.bsky.social @uvsq.bsky.social #ucl @cbm-csic-uam.bsky.social @varechavala.bsky.social
February 28, 2025 at 10:58 AM
🚨 Only 3 Weeks Left to Apply! 🚨
Passionate about antisense oligonucleotide (ASO) therapeutics? Looking for a PhD opportunity in this cutting-edge field? The EFFecT consortium is recruiting!
February 17, 2025 at 4:48 PM
Check out our latest work! Preclinical in vitro and safety and in vivo biodistribution of #antisense #oligonucleotides targeting a recurrent genetic variant in ABCA4 present in patients with #Stargardt disease. A big first step towards therapeutic intervention.
www.nature.com/articles/s43...
Preclinical assessment of splicing modulation therapy for ABCA4 variant c.768G>T in Stargardt disease - Communications Medicine
Karjosukarso et al. investigate antisense oligonucleotides targeting aberrant splicing caused by a recurrent ABCA4 variant in Stargardt disease. A candidate therapeutic molecule that shows a favorable...
www.nature.com
January 25, 2025 at 8:14 AM
Today part of the @dutch-antisense.bsky.social organizing committee visited the venues for the #DATS2025 in Groningen! We cannot wait to welcoming you in June! Registrations will open soon, stay tuned! www.dutchantisense.org
@ronaldbuijsen.bsky.social
January 24, 2025 at 11:30 PM